Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.35 |
| ▸ | TYRO3 | Q06418 | 7/20 | 0.35 |
| ▸ | AXL | P30530 | 3/20 | 0.33 |
| ▸ | MERTK | Q12866 | 2/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.31 |
| ▸ | PI4KA | P42356 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16610909 | 0.94 | LRRK2 (0.40) | LRRK2NR3C1TGFBR1TYRO3AXL | |
| SCHEMBL16611086 | 0.91 | AXL (0.33) | TYRO3AXLMERTKPIK3CGPIK3CD | |
| SCHEMBL16611389 | 0.90 | AXL (0.33) | NR3C1TYRO3AXLMERTKPIK3CG | |
| SCHEMBL16611264 | 0.88 | LRRK2 (0.35) | LRRK2TYRO3AXL | |
| SCHEMBL16611382 | 0.78 | SLC22A12 (0.33) | LRRK2NR3C1 | |
| SCHEMBL16611225 | 0.75 | TGFBR1 (0.42) | LRRK2TGFBR1MERTKPIK3CGPIK3CD | |
| SCHEMBL16611177 | 0.74 | KHK (0.40) | — | |
| SCHEMBL16611033 | 0.72 | CHRM3 (0.32) | LRRK2TGFBR1 | |
| SCHEMBL16610780 | 0.70 | CNR1 (0.43) | — | |
| SCHEMBL16610898 | 0.69 | LRRK2 (0.43) | LRRK2TGFBR1PIK3CGPIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857400-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | LRRK2 1393/4885NR3C1 1663/4885TGFBR1 1544/4885 |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | LRRK2 1393/4885NR3C1 1663/4885TGFBR1 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.